StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Summit Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Summit Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$458.43M. For fiscal 2025 it was -$322.93M. The highest annual figure on record is -$35.11M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$322.93M–
FY2024Dec 31, 2024-$142.11M–
FY2023Dec 31, 2023-$76.76M–
FY2022Dec 31, 2022-$41.58M–
FY2021Dec 31, 2021-$72.59M–
FY2019Jan 31, 2019-$35.11M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$141.12M–
Q1 FY2026CQ1 2026Mar 31, 2026-$122.29M–
Q4 FY2025CQ4 2025Dec 31, 2025-$101.94M–
Q3 FY2025CQ3 2025Sep 30, 2025-$93.08M–
Q2 FY2025CQ2 2025Jun 30, 2025-$66.74M–
Q1 FY2025CQ1 2025Mar 31, 2025-$61.17M–
Q4 FY2024CQ4 2024Dec 31, 2024-$48.67M–
Q3 FY2024CQ3 2024Sep 30, 2024-$30.30M–
Q2 FY2024CQ2 2024Jun 30, 2024-$33.00M–
Q1 FY2024CQ1 2024Mar 31, 2024-$30.13M–
Q4 FY2023CQ4 2023Dec 31, 2023-$19.46M-474.9%
Q3 FY2023CQ3 2023Sep 30, 2023-$14.90M–
Q2 FY2023CQ2 2023Jun 30, 2023-$29.27M–
Q1 FY2023CQ1 2023Mar 31, 2023-$13.13M–
Q4 FY2022CQ4 2022Dec 31, 2022$5.19M–
Q3 FY2022CQ3 2022Sep 30, 2022-$8.56M–
Q2 FY2022CQ2 2022Jun 30, 2022-$19.22M–
Q1 FY2022CQ1 2022Mar 31, 2022-$19.00M–
Q4 FY2021CQ4 2021Dec 31, 2021-$9.18M–
Q3 FY2021CQ3 2021Sep 30, 2021-$23.57M–
Q2 FY2021CQ2 2021Jun 30, 2021-$19.17M–
Q1 FY2021CQ1 2021Mar 31, 2021-$20.67M–

More Summit Therapeutics figures

See a number that looks wrong?